الفهرس 
List of contentsOnly 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
The current study was performed prospectively in Assiut University hospital to evaluate the efficacy of hepatitis B vaccine among students of Assiut nursing school and college in the period between November 2016 and November 2017.
A total of 100 students were enrolled, the mean age of enrolled subjects was 21.65 ± 1.31 years with range between 18 and 24 years. The majority (70%) of them were males and 60% of them came from rural areas. It was noticed that 10 (10%) of candidates were previously had received only a single dose of hepatitis B vaccination 6-12 months before starting the study.
All the enrolled candidates were with no history of medical diseases nor a risk of exposure to HBV infection with no signs of liver disease and also all were with negative testing for HBsAg, HCV Ab andanti-HBcAbwith normal abdominal ultrasonography.
All the enrolled candidates were subjected to prevaccination detection of anti HBs-Ab level and all were negative (less than 10 IU/L) then they took hepatitis B vaccine (EUVAX-B 20mcg/mL) according to the schedule (0,1,2 month) with a dose of 1mL by intramuscular route at deltoid region by the nursing staff members of vaccination clinic at Tropical Medicine and Gastroenterology department inAssiut University Hospitals then a second blood sample was withdrawn 1 month after the last vaccination dose to evaluate anti-HBs Ab response.
As regard anti-HBs Ab response, seroprotection rate was 100%, ie; all enrolled candidates show post vaccination anti-HB Abtitre>10 IU/L (4.07 ± 2.62 vs. 66.44 ± 11.61; P< 0.001).
As regard those who previously received hepatitis B vaccine dose 6-12 months before the study we noticed that all of them had high anti-HBs Abtitre level either before (9.78 ± 2.01 vs. 3.43 ± 1.89; P< 0.001) or after (179.50 ± 40.11 vs. 53.87 ± 19.08; P< 0.001) the study in comparison to naïve candidate after vaccination.
According to the level of pre vaccination anti-HB Abtitre, Post vaccination anti-HBs Abtitre was vary as high >100 IU/L or low <100 IU/L according toits prevaccination level (8.57 ± 1.59 vs. 3.14 ± 1.16 IU/L, P< 0.001) respectively, ie; the more pre vaccination anti-HBs Ab tire, the more its post vaccination level and also the more protection against HBV infection.
In our study, we had noticed that level of anti-HBs Ab was higher in female subjects in comparison to male subjects (69.53 ± 6.89 vs. 65.11 ± 12.09; P= 0.69) but without significant statistical difference (P Value= 0.69).
The level of anti-HBs Ab was insignificantly higher in those with age group 20 years old or more in comparison to those with age group less than 20 years old (68.46 ± 10.56 vs. 50.09 ± 12.56; P= 0.25).